|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-10-9
|
|
pubmed:abstractText |
Ketoconazole is a commonly used secondary hormonal therapy in castration-refractory prostate cancer (CRPC), but disease progression inevitably occurs. Both prostatic and metastatic lesions in patients with CRPC overexpress 5-alpha reductase (SRDA5) type I. We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1938-0682
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
E90-2
|
|
pubmed:meshHeading |
pubmed-meshheading:19815488-Aged,
pubmed-meshheading:19815488-Antineoplastic Agents, Hormonal,
pubmed-meshheading:19815488-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19815488-Azasteroids,
pubmed-meshheading:19815488-Disease Progression,
pubmed-meshheading:19815488-Humans,
pubmed-meshheading:19815488-Ketoconazole,
pubmed-meshheading:19815488-Male,
pubmed-meshheading:19815488-Middle Aged,
pubmed-meshheading:19815488-Orchiectomy,
pubmed-meshheading:19815488-Prostatic Neoplasms,
pubmed-meshheading:19815488-Tumor Markers, Biological
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Boston, MA, USA. osartor@tulane.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
